Today, June 8, 2016, the subscription period commences regarding ExpreS2ion Biotech Holding AB’s (“ExpreS2ion”) initial public offering before the planned listing on the Nasdaq Stockholm First North. The subscription period runs until June 22, 2016. A full subscription will raise proceeds of about 18 MSEK for ExpreS2ion, before issue costs. The company has already binding subscription commitments of approximately 7.5 MSEK and a guarantee commitment of 1 MSEK, which in total equals about 48 percent of the issue volume. Memorandum, teaser and application form (in Swedish) are available for download on ExpreS2ion’s (www.expres2ionbio.com) and Sedermera Fondkommissions’ (www.sedermera.se) respective websites.

Read the whole press release (pdf)